Small-cap biotech companies can deliver outsized returns over the long run if they develop breakthrough medicines that go on to generate massive sales. However, some of these smaller drugmakers aren't ...

Schrödinger (NASDAQ: SDGR) and Recursion Pharmaceuticals (NASDAQ: RXRX) are both biotechs that want to use AI to streamline the drug discovery and development process. And that makes them hot stocks ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

Recursion is scheduled to report its first quarter 2025 financial results, providing transparency and updates to investors, which can enhance trust and investor relations. The company'searnings ...

Recursion Pharmaceuticals has an exciting approach to developing therapies. The company recently reported positive phase 2 results for one of its products. While this small biotech looks promising, it ...